Photocure ASA (PHCUF)

Market Cap	172.96M +34.4%
Revenue (ttm)	68.98M +26.1%
Net Income	8.66M +3,843.5%
EPS	0.32 +3,902.5%
Shares Out	n/a
PE Ratio	19.98
Forward PE	23.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	120
Open	7.39
Previous Close	7.07
Day's Range	7.39 - 7.39
52-Week Range	4.95 - 7.39
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 29, 2026

About Photocure ASA

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia. The company has a license agreement with Asieris MediTech Co to develop...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 100
• Stock Exchange: OTCMKTS
• Ticker Symbol: PHCUF

Financial Performance

In 2025, Photocure ASA's revenue was 532.58 million, an increase of 1.37% compared to the previous year's 525.39 million. Losses were -1.52 million, -54.58% less than in 2024.

Financial numbers in NOK